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Abstract
Olfactory dysfunction is associated with normal aging, multiple neurodegenerative disorders, including Parkinson’s disease, Lewy body disease and Alzheimer’s disease, and other
diseases such as diabetes, sleep apnea and the autoimmune disease myasthenia gravis.
The wide spectrum of neurodegenerative disorders associated with olfactory dysfunction
suggests different, potentially overlapping, underlying pathophysiologies. Studying olfactory
dysfunction in presymptomatic carriers of mutations known to cause familial parkinsonism
provides unique opportunities to understand the role of genetic factors, delineate the salient
characteristics of the onset of olfactory dysfunction, and understand when it starts relative to
motor and cognitive symptoms. We evaluated olfactory dysfunction in 28 carriers of two
MAPT mutations (p.N279K, p.P301L), which cause frontotemporal dementia with parkinsonism, using the University of Pennsylvania Smell Identification Test. Olfactory dysfunction
in carriers does not appear to be allele specific, but is strongly age-dependent and precedes
symptomatic onset. Severe olfactory dysfunction, however, is not a fully penetrant trait at
the time of symptom onset. Principal component analysis revealed that olfactory dysfunction
is not odor-class specific, even though individual odor responses cluster kindred members
according to genetic and disease status. Strikingly, carriers with incipient olfactory dysfunction show poor inter-test consistency among the sets of odors identified incorrectly in successive replicate tests, even before severe olfactory dysfunction appears. Furthermore,
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when 78 individuals without neurodegenerative disease and 14 individuals with sporadic
Parkinson’s disease were evaluated twice at a one-year interval using the Brief Smell Identification Test, the majority also showed inconsistency in the sets of odors they identified
incorrectly, independent of age and cognitive status. While these findings may reflect the
limitations of these tests used and the sample sizes, olfactory dysfunction appears to be
associated with the inability to identify odors reliably and consistently, not with the loss of an
ability to identify specific odors. Irreproducibility in odor identification appears to be a nondisease-specific, general feature of olfactory dysfunction that is accelerated or accentuated
in neurodegenerative disease. It may reflect a fundamental organizational principle of the
olfactory system, which is more “error-prone” than other sensory systems.

Introduction
Olfactory dysfunction is seen in normal aging [1] and diverse diseases including diabetes [2]
sleep apnea [3], and the autoimmune disease myasthenia gravis [4]. In particular, it is a common non-motor manifestation in neurodegenerative diseases, including Parkinson’s disease,
Alzheimer’s disease, spinocerebellar ataxia and corticobasal degeneration, as well as in
frontotemporal dementia (FTD), which is characterized by behavioral, language, and cognitive
manifestations, and the form of FTD linked to chromosome 17 in which parkinsonism is
prominent, FTDP-17 [5–12]. In genetic and sporadic forms of neurodegenerative disease,
olfactory dysfunction sometimes precedes motor or cognitive symptoms and so has been
discussed as a biomarker that may improve diagnostic accuracy [13–17]. For example, it is
present in REM sleep behavior disorder, which often precedes Parkinson’s disease motor manifestations by at least four years [13,18]. A fuller understanding of both its value and limitations
as a biomarker for neurodegenerative disease can be obtained by characterizing the features of
olfactory dysfunction in presymptomatic and symptomatic carriers of highly penetrant mutations that cause neurodegeneration [16,17]. Even though there are often relatively few individuals who can be evaluated, since disease in mutation carriers is highly penetrant, and issues of
genetic variability are considerably less than in the general population, studying olfactory dysfunction in carriers offers the possibility of unique insights into the progression of olfactory
dysfunction during the pre-symptomatic and symptomatic phases of neurodegenerative disease. In addition to defining an understanding of the salient characteristics of olfactory dysfunction relevant to its function as a biomarker, such studies also have the potential to offer
insights into the process of olfaction itself.
Here, we follow this rationale and assess olfactory dysfunction in carriers of MAPT mutations who develop FTDP-17. FTD is phenotypically and genetically heterogeneous, being associated with mutations in MAPT, GRN, TARDBP, FUS, C9ORF72, VCP, and CHMP2B [19].
MAPT mutations have been identified in multiple FTDP-17 kindreds [19,20]. Most MAPT
point mutations cluster in the gene region encoding tau’s microtubule-binding domain. Different mutations can affect alternative splicing, tau-isoform ratios, and/or tau-protein levels
and are associated with different clinical, molecular and neuropathological outcomes [21–24].
The p.N279K mutation is among those that affect tau pre-mRNA splicing, which are associated predominantly with gray matter loss in the medial temporal lobe, while the p.P301L
mutation is among those that affect tau-protein structure, which are associated with gray matter loss in the lateral temporal lobe and relative sparing of the medial temporal lobe [25].
Because the p.N279K and p.P301L MAPT mutations have different phenotypic consequences,
evaluating whether olfactory dysfunction differs in carriers of these mutations can provide
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unique insight into whether and how differences in genotype contribute to the severity and the
character of olfactory dysfunction associated with neurodegenerative disease.
Therefore, we characterized the features of olfactory dysfunction in carriers having these
two MAPT mutations. We sought to address whether there is an allele-specific effect on the
onset or severity of olfactory dysfunction, whether severe olfactory dysfunction is a fully penetrant trait prior to symptom onset, whether it typically occurs prior to the onset of cognitive
and motor symptoms, its age dependence and rate of progression, whether it is reversible, and
whether genetic background influences the pattern of odors able to be identified. We then
evaluated two possible explanations for olfactory dysfunction–that it is associated with the
inability to identify specific odors, or that it is associated with the inability to identify all odors
reliably and consistently. For this, we first analyzed data from the MAPT kindreds, and then
evaluated whether our findings for this specific issue were generalizable by analyzing data
from a cohort with sporadic Parkinson’s disease and a cohort of aging subjects without neurodegenerative disease. Insights into these questions have the potential to significantly impact
investigations into the mechanisms that underlie olfactory dysfunction as well as normal olfactory processing.

Materials and Methods
Ethics Statement
This study was approved by the Mayo Clinic Institutional Review Boards (Clinical and Genetic
Studies of Neurodegenerative Syndromes, Dystonia and Restless Leg Syndrome, IRB 1087–
98), the Bioethics Committee of the Medical University of Gdańsk (The role of neuropsychological assessment and neuroimaging in the early detection of frontotemporal dementia and
parkinsonism linked to chromosome 17 (FTDP-17), Polish Ministry of Science and Higher
Education project: IP 2010 037870, approval: 135/2011), and the Ethikkommision der Universität zu Lübeck (EPIPARK, approvals 09–069, 15–082). Study subjects were evaluated following written informed consent.

Study Design
The questions addressed in this study, and the methods used to investigate them, are diagrammed in the flowchart presented in Fig 1. Our initial focus was to define the characteristics
of the onset and progression of olfactory dysfunction in two kindreds with MAPT-associated
FTDP-17. These were the pallido-ponto-nigral-degeneration kindred (PPND) with the p.
N279K MAPT mutation, and the Gdańsk kindred with the p.P301L MAPT mutation [24,26,27].
The 40-odor forced-choice University of Pennsylvania Smell Identification Test (UPSIT) [28]
was used to assess olfactory function, and sex- and age percentile norms based on 1819 men
and 2109 women provided with the UPSIT by Sensonics, Inc. were used to assign the percentile
associated with a subject’s UPSIT score and to interpret olfactory status as either normosmia,
mild microsmia, moderate microsmia, severe microsmia, or anosmia.
Since individuals with these specific MAPT mutations are rare, the sample size was limited
to the number of kindred members who gave informed consent. In the PPND kindred, we
obtained UPSIT data from 20 p.N279K carriers and from 11 mutation-negative kindred members who, since they most closely reflect the genetic background of mutation-positive kindred
members, served as controls. In the Gdańsk kindred, we obtained UPSIT data from eight p.
P301L carriers (two additional carriers were specifically excluded because of severe cognitive
impairment). Eight age- and education-matched subjects were evaluated as controls, as mutation-negative family-member controls were unavailable for testing. An analysis of these data
allowed us to address whether the onset or severity of olfactory dysfunction differs between
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Fig 1. Study questions and analytical approaches.
doi:10.1371/journal.pone.0165112.g001
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individuals with different mutant MAPT alleles, whether severe olfactory dysfunction always
occurs, and whether it typically occurs prior to symptom onset.
We then used serial UPSIT administration to determine when and how rapidly olfactory
dysfunction occurs. Nine PPND kindred members–eight carriers, one mutation-negative–
agreed to participate in this aspect of the study. These nine subjects were assessed two to four
times with a median inter-test interval of 14 months (inter-test range: 6 to 34 months). The
inter-test interval timing was at least six months to minimize the influence of prior testing.
When there was a delay in testing, it was due to the availability of the subject for testing. Replicate UPSIT data are useful for documenting whether replicate UPSITs give stable scores,
whether olfactory dysfunction shows any evidence of reversibility, and whether the progression of olfactory dysfunction can be monitored using UPSITs. Analysis of individual UPSIT
odors using principal components analysis (PCA) and analysis of the odors identified in replicate UPSITs allowed us to address whether individual carriers lose their ability to identify specific odors, whether the inability to identify an odor in sequential pairs of UPSITs is
reproducible, and whether a subset of study subjects exhibit a bias in the pattern of odors they
identify using the UPSIT.
Analysis of the results of serial UPSITs in PPND kindred members indicated that the pattern of odors identified in successive UPSITs is often irreproducible (see Results). Therefore,
we asked whether odor-identification irreproducibility is also seen in sporadic Parkinson’s disease, and whether it might be a general feature of olfactory dysfunction unrelated to neurodegenerative disease. For this, we retrospectively analyzed differences between annual tests of
olfactory function of individuals participating in the EPIPARK study [29]. The EPIPARK
study recruited and is following longitudinally 623 members of a representative, populationbased cohort from Lübeck, Germany to investigate non-motor symptoms in parkinsonism. In
this study, participants were asked to self-report major disease and medical treatments, including medications, socio-economic position, and family history for parkinsonism, and initially
underwent transcranial ultrasound of the substantia nigra. Initially and at yearly intervals, the
following tests were administered: Mini-Mental State Examination (MMSE) [30,31]; Montreal
Cognitive Assessment (MoCA) [32,33]; Parkinson Neuropsychometric Dementia Assessment
(PANDA) [34]; Unified Parkinson’s Disease Rating Scale (UPDRS I-IV) [35,36]; major depression questions from the Structured Clinical Interview for DSM IV (SCID) [37]; axis I screening
questions from SCID interview; recording of Hoehn and Yahr [38] and Schwab and England
activities of daily living scales [39]; Archimedes spiral test and a handwriting sample; and the
Brief Smell Identification test (BSIT) [40,41], an abbreviated version of the UPSIT test having
a 12-odor subset selected from those in the UPSIT. To address the issue of odor identification
irreproducibility, we analyzed BSIT and MoCA data gathered in two successive years from 14
individuals with Parkinson’s disease (an established diagnosis of Parkinson’s disease at each
test or at just the second test) and 78 individuals who showed no evidence of neurodegenerative disease. The number of enrolled EPIPARK participants in the Parkinson’s disease and
control groups who were twice administered the same version of the BSIT determined by sample sizes of these groups.
In all parts of these investigations, blinding or randomization was impossible given the
nature of the study subjects and objectives, however, the clinicians who obtained clinical data
and performed olfactory assessment were not involved in data analysis.

Olfactory testing
The UPSIT was initially administered to 12 p.N279K manifesting carriers (MCs), eight nonmanifesting carriers (NMCs), 11 mutation-negative PPND family member controls, three p.
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P301L MCs, five p.P301L NMCs, and eight non-Gdańsk-kindred controls. Study subjects provided only general information on their smoking status. Nine PPND individuals–four NMCs,
four MC, and one control–underwent additional UPSIT testing at a median inter-test interval
of 14 months. Of these, three NMCs did not change disease status in subsequent tests: one had
a one duplicate test after nine months; two had three additional tests with inter-test intervals of
14, 15, and 24, or 14, 29, and 10 months. The fourth NMC was symptomatic (i.e., a MC) when
a duplicate test was administered 34 months later. Of the four initially tested MCs, three had
duplicate tests with inter-test intervals of 6, 9, and 34 months, while one had two additional
tests with inter-test intervals of 17 and 28 months. The control individual had a duplicate test
after 17 months.
For members of the EPIPARK cohort, we analyzed data from administration of BSITs and
MoCAs administered at approximately one-year intervals (13.3 ± 3.4 months). At the second
test, the mean age of 78 individuals without evidence of neurodegenerative disease was
67.3 ± 6.5 years and the mean age of 14 individuals with Parkinson’s disease was 70.9 ± 10.4
years. Two of the three available versions of the BSIT were used: 74 subjects, five with Parkinson’s disease, were tested twice using the BSIT; 18 subjects, nine with Parkinson’s disease, were
tested twice using version A of the BSIT.

Statistical analysis
Data were analyzed using non-parametric descriptive statistics, PCA, and kernel density estimation with R [42] or SPSS. The Mann-Whitney U or Kruskal-Wallis tests and the median
test were used to evaluate inter-group differences in the distribution and median, respectively,
of UPSIT scores. Spearman’s ρ was used to evaluate the strength of the relationship of UPSIT
scores to age at test, mutation status, smoking and sex. An alpha-level of P < 0.05 was interpreted as significant. Kernel density estimation, using a Gaussian kernel density estimator, was
used to estimate the probability density function relating UPSIT scores to age-at-test. PCA was
used to evaluate two alternative hypotheses: 1) single or sets of UPSIT odors contributed differentially to UPSIT scores associated with olfactory dysfunction, or 2) odors were equally likely
to be misidentified. Cohen’s kappa (κ), an index that measures inter-rater agreement for categorical items and takes into account agreement occurring by chance, was used to assess variability in an individual subject’s olfactory performance on successive UPSITs or BSITs. This
measure, which is frequently used to evaluate agreement between different individuals, has
also been used to evaluate inter-rater reliability (e.g., [43]) and is useful here since replicate
tests of olfactory function made at six month or longer intervals should not be influenced by
the memory of prior testing and can therefore be treated as independent assessments. Therefore, κ was used to evaluate how reproducibly a subject identified or misidentified individual
odors in successive UPSIT and BSIT assessments.

Results
Clinical Information
PPND family. The PPND family is among the largest FTDP-17 kindreds with 57 MCs. Its
clinical presentation has been described previously [24–26,44–46], and includes rigidity, bradykinesia, personality changes, dementia, dystonia, gaze palsy and postural instability. The
average age of onset in this kindred is 43 years and the average disease duration is eight years.
Olfactory function was previously characterized in six affected members [44]. An individual
was considered to be an MC, in both the PPND and the Gdańsk kindreds, following the
appearance of either a cognitive or motor symptom. Tested MCs are shown as enlarged symbols in the updated pedigree in Fig 2, and clinical and UPSIT data are provided in Table 1.
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Fig 2. The PPND family and Branches 1 and 2 of the Gdańsk family. Squares, male members; circles, female members; filled symbols; affected
mutation carriers; numbers inside symbols, number of siblings; roman numerals, generations; Arabic numerals to the right lower side of a symbol, position
in the pedigree, diagonal lines through symbols, deceased. Enlarged symbols identify manifesting carriers in whom UPSITs were administered.
doi:10.1371/journal.pone.0165112.g002

Except for MCs and V-5, the NMC who became symptomatic in the inter-UPSIT interval,
tested NMCs and controls are not identified to protect subject confidentiality.
At the time of their initial UPSIT, the 12 MCs from the PPND kindred (five males, seven
females) had a mean age at test of 46.7 ± 4.6 years. Their mean age of onset was 43.5 ± 4.0
years and mean disease duration at test was 3.2 ± 1.4 years. Excluding V-37, a surviving individual, the mean disease duration in MCs was 6.5 ± 2.0 years. At the time of their initial
UPSIT, the mean age at test of the eight NMCs and 11 mutation-negative PPND family member controls was 34.2 ± 8.4 and 39.6 ± 14.7 years, respectively.
Gdańsk family. The Gdańsk family is the first family from Central-Eastern Europe whose
FTDP phenotype associates with the p.P301L mutation [27]. In contrast to previous reports

Table 1. Clinical information and UPSIT Scores of p.N279K and p.P301L Carriers Identified in Fig 2, and Gdańsk controls.
PedigreeNumber1 Sex Smoker Status2 Age at
Onset

Disease Duration at
Death

Age at
Test

UPSIT
Score

UPSIT Norms
Percentile3

Interpretation3

IV-14 (P)

F

Yes

MC

51

6.2

54.3

10

5

Anosmia

IV-18 (P)

M

Yes

MC

45

6.2

48.4

11

5

Anosmia

V-5 (P)

F

No

NMC

46

2.6

44.8

12

5

Anosmia

“ “

“

“

MC

“

“

47.6

11

5

Anosmia

V-6 (P)

M

No

MC

41

9.8

42.4

11

5

Anosmia

“ “

“

“

MC

“

“

45.2

7

5

Anosmia

V-9 (P)

M

Yes

MC

41

9.2

45.6

10

5

Anosmia

V-12 (P)

F

No

MC

43

8.0

49.8

11

5

Anosmia

V-17 (P)

F

No

MC

39

5.6

41.7

10

5

Anosmia

“ “

“

“

MC

“

“

42.4

12

5

Anosmia

V-18 (P)

F

No

MC

46

7.1

48.9

10

5

Anosmia

V-33 (P)

F

No

MC

48

4.8

51.1

15

5

Anosmia

V-37 (P)

M

Yes

MC

47

−

50.8

10

5

Anosmia

V-38 (P)

F

Yes

MC

44

3.5

46.6

12

5

Anosmia

VI-22 (P)

M

No

MC

38

3.6

39.7

33

12

Mild microsmia

“ “

“

“

MC

38

“

40.2

30

8

Mild microsmia

VI-29 (P)

F

No

MC

39

7.4

41.6

11

5

Anosmia

“ “

“

“

MC

39

“

43.0

7

5

Anosmia

“ “

“

“

MC

39

"

45.3

8

5

Anosmia

III-3 (G)

M

Yes

MC

48

4

52

8

5

Anosmia

III-3 (G) control

M

No

Control

−

−

52

36

60

Normosmia

III-4 (G)

M

No

MC

49.5

6.5

56

29

19

Moderate
microsmia

III-4 (G) control

M

No

Control

−

−

56

33

27

Mild microsmia

III-5 (G)

M

Yes

MC

46

1

46

15

5

Anosmia

III-5 (G) control

M

Yes

Control

−

−

47

28

6

Moderate
microsmia

1

P = PPND family, G = Gdańsk family

2

MC = manifesting carrier, NMC = nonmanifesting carrier, Control = healthy individual pair-matched for sex, age and education
Based on UPSIT age and sex percentile norms provided by Sensonics, Inc.

3

doi:10.1371/journal.pone.0165112.t001
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for this mutation, symptomatic individuals from the Gdańsk family show atypical neurological
and neuropsychological manifestations, such as unilateral resting tremor and hemi-spatial
neglect [47]. Symptoms include behavioral abnormalities and depression. Parkinsonism develops within five years and includes bradykinesia, bradyphrenia, unilateral tremor, postural
instability, and falls. With disease progression, epileptic seizures, vertical gaze palsy, and hemispatial neglect are seen. The mean disease duration is ten years.
The Gdańsk family consists of two branches (Fig 2). The individuals tested–five NMCs
from Branch I and three male MCs from Branch II–are shown as enlarged symbols. Clinical
information on the MCs and their controls are shown in Table 1. Two affected individuals displayed behavioral and cognitive impairment without parkinsonism [27,47].
For MCs, the mean age at test was 51.3 ± 5.0 years, the mean age of onset was 47.8 ± 1.8
years, and the mean disease duration at test was 3.3 ± 4.2 years. The mean age at test of NMCs
and the eight pair-matched, mutation-negative individuals was 30.0 ± 2.7 and 37.6 ± 12.1
years, respectively.

Salient Characteristics of MAPT-Related Olfactory Dysfunction
Olfactory dysfunction does not appear to be allele-specific. Examination of the distribution of the UPSIT scores, considering only the initial scores of subjects administered multiple
UPSITs, from the PPND and Gdańsk families reveals that most MCs have severe olfactory dysfunction, while NMCs have a wide range of UPSIT scores that spans between those of MCs
and controls. As shown in Fig 3A, in the PPND family, MCs have a lower median and narrower distribution of UPSIT scores than controls (P < 0.001 for both), MCs have a lower
median and narrower distribution of UPSIT scores than NMCs (P = 0.001 for both), and carriers (MCs and NMCs) show a wider distribution of UPSIT scores than controls (P = 0.011). In
the Gdańsk family, the distribution of UPSIT scores is wider in MCs than in controls
(P = 0.024). No significant differences in the median or distribution of UPSIT scores were
identified, however, when just MCs, NMCs, or controls from one family were compared to the
other. While the small sample size in the Gdańsk kindred may preclude identifying significant
differences, these data suggest that olfactory dysfunction is not allele specific.
Severe olfactory dysfunction is not a fully penetrant trait. When UPSIT data for MCs,
NMCs, and controls from each family are combined, it becomes apparent that even though all
MCs have impaired olfactory function, not all have low, or even similar, UPSIT scores. In Fig
3A, the box plots for MCs in the combined data identify two outliers: VI-22 with mild microsmia (UPSIT = 33 at age 39.7, 12th percentile of male norms) and Gdańsk III-4 with moderate
microsmia (UPSIT = 29 at age 56, 19th percentile of male norms). Since both of these outliers
are non-smokers, and smoking can negatively affect UPSIT scores, one concern is whether
these individuals are outliers because they are not smokers while other MCs are smokers.
Smoking status seems unlikely to be the only factor, as three relatively young nonsmoker MCs
in the PPND family (V-6, V-17, and VI-29, tested at ages 41.6 to 42.4) are anosmic with USPIT
scores 10 and 11 ( 5th percentile of sex and age norms). Hence, severe olfactory dysfunction
is not a fully penetrant trait at the time of symptom onset in MCs with either of these MAPT
mutations.
Olfactory dysfunction typically occurs prior to symptom onset. To evaluate whether
olfactory dysfunction typically occurs prior to symptom onset, the ages of MCs and NMCs
were compared after grouping them based on whether their (initial) UPSIT score was above or
below the 20th percentile of sex and age UPSIT norms. Fig 3B shows the age distribution of
these subject groups. The only individuals with UPSIT scores above the 20th percentile were
NMCs, who were also normosmic. All MCs had UPSIT scores below the 20th percentile, as did
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Fig 3. Characterization of olfactory dysfunction in MAPT mutation carriers. (A) UPSIT scores differ between MAPT carriers and controls. The
initial UPSIT scores obtained from MCs, NMCs, and familial (for PPND) or pair-matched (for Gdańsk) controls are presented as boxplots showing the
medians and interquartile distributions. The boxplot width is proportional to the number of subjects in each group. The main legend shows the symbols that
are used throughout this figure to convey genetic and symptomatic status. Here and in panel B, the symbols #, ##, ### and *, **, *** identify differences
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between groups significant at the P < 0.05, 0.01, or 0.001 levels, in either the median (median test) or distribution (Mann-Whitney U or Kruskal-Wallis tests),
respectively. Outliers are shown and labeled here and in panels C and D using the pedigree identifiers from Fig 2 and P for PPND or G for Gdańsk.
Differences in the distribution or median of UPSIT scores between the controls, NMCs, or MCs of each kindred were not significant, so differences between
these groups were also assessed after pooling data from both kindreds. In the combined data, MCs as well as all carriers have different distributions and
lower median UPSIT scores than controls, and MCs have a narrower distribution and lower median UPSIT score than either NMCs or controls. (B)
Olfactory dysfunction precedes symptomatic onset in p.N279K and p.P301L carriers. The initial UPSIT scores of carriers used in part A are replotted
as a function of age after grouping carriers by whether their UPSIT score falls below the 20th percentile of UPSIT-score sex and age population norms. In
this study, all NMCs above this cutoff were normosmic. Among individuals with UPSIT scores below the 20th percentile, NMCs have a wider age distribution
and a younger median age than MCs. (C) As carriers approach their fourth decade, their UPSIT scores show an accelerated decline. Though UPSIT
scores remain relatively stable in replicate tests, individual odors are not identified reproducibly. UPSIT scores of PPND and Gdańsk kindred
members and controls are plotted relative to age at test. The 50th and 95th percentile distribution of kernel density plots for MCs, NMCs, and controls are
drawn. These indicate that, except for the outliers identified in Panel A (labeled and marked here with a dot), olfactory function in NMCs, compared to that in
controls, declines precipitously near the start of the fourth decade and that MCs have very low (15) UPSIT scores early in their fourth decade. Two to four
UPSITs were obtained from nine PPND kindred members at a median inter-UPSIT interval of 14 months (inter-test range: 6–34 months; for details, see
Methods). Lines connect the data points (marked with a dot) for successive UPSITs in each individual, highlighting that UPSIT scores are relatively stable
over the tested intervals. (D) Principal component analysis using individual odor scores separates study subjects according to affected status
and kindred. The scores of the first and second components from PCA using only individual odor scores, each centered and scaled to have unit variance,
are shown in a scatterplot. Outliers and individuals with replicate UPSITs are presented as in panel C. With the exception of two outliers (Gdańsk III-4 and
PPND VI-22), PC1 distributes MCs separately from controls, while NMCs are mixed among both controls and MCs. PC2 tends to distribute NMCs and
controls, but not MCs, by kindred.
doi:10.1371/journal.pone.0165112.g003

most NMCs. Among individuals with UPSIT scores below the 20th percentile, however, the
median age of MCs was higher than that of NMCs (P = 0.004), and the distribution of ages of
MCs was narrower than that of NMCs (P < 0.001). As discussed above, some olfactory function can be preserved in atypical outliers. PPND VI-22 at age 40 had an UPSIT of 30 (8th percentile), while all other p.N279K MCs were over age 41 and anosmic. Gdańsk III-4 at 56 had
an UPSIT of 29 (19th percentile). Though older than the other two MCs in the Gdańsk kindred,
and having longer disease duration (6.5 versus 0 and 4 years), he had retained greater olfactory
function. Nonetheless, substantial olfactory dysfunction occurs in mutation carriers before
symptom onset.
Olfactory function declines irreversibly and precipitously near the start of the fourth
decade. Analyses using initial UPSIT scores showed that they decline strongly with increasing age at test in all carriers and in just PPND carriers (all: Pearson’s ρ = −0.723, P < 0.01,
2-tailed; PPND: ρ = −0.738, P < 0.01; Gdańsk: ρ = −0.475, P = 0.234) but not in any group of
controls (all: ρ = 0.149, P = 0.542; PPND: ρ = 0.074, P = 0.828; Gdańsk: ρ = 0.218, P = 0.604).
Since smoking is known to influence UPSIT scores, we also assessed the whether UPSIT scores
were correlated with smoking in carriers or controls. In contrast to the strong relationship
seen between UPSIT scores and age at test in carriers, UPSIT scores showed only negligible or
low, but always insignificant correlations with smoking in either carriers (all: ρ = −0.161,
P = 0.414; PPND: ρ = −0.323, P = 0.165; Gdańsk: ρ = −0.063, P = 0.881) or in all controls and
just PPND controls (all: ρ = −0.155, P = 0.527; PPND: ρ = 0.330, P = 0.322). Smoking did a
strong and significant negative correlation with UPSIT scores in Gdańsk controls (ρ = −0.765,
P = 0.027), however. We also found that there was no significant relationship between sex and
UPSIT in carriers (all: ρ = −0.121, P = 0.538; PPND: ρ = 0.000, P = 1.000; Gdańsk: ρ = −0.604,
P = 0.113), or in controls (all: ρ = 0.019, P = 0.937; PPND: ρ = 0.147, P = 0.665; Gdańsk: ρ =
−0.110, P = 0.795). These analyses indicate that, while smoking is able to negatively affect
UPSIT scores, it does not strongly correlate with the UPSIT scores of the carriers in this study,
and so not, by itself, account for the decline of UPSIT scores in carriers. In contrast, increasing
age at test strongly and negatively affects UPSIT scores in carriers but not controls.
To better evaluate how the distribution of UPSIT scores changes during aging, nonparametric kernel density estimation, using a Guassian kernel density estimator, was used to
estimate the probability density function describing how UPSIT scores change during aging.
The 50th and 95th percentile distributions for controls, NMCs, and MCs are drawn in Fig 3C.
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With the notable exception of the previously discussed outliers, olfactory function in NMCs,
which until the late third decade overlaps with that of controls, declines precipitously near the
start of the fourth decade so that, at the typical time of symptom onset, MCs have very low
(15) UPSIT scores.
To evaluate the whether olfactory dysfunction is irreversible, address the stability of UPSIT
scores over time, and attempt to follow the timing of the onset and progression of olfactory
dysfunction in single individuals, we obtained serial UPSITs from nine PPND kindred members (one gene-negative family member, four MCs, three NMCs and one NMC who manifested symptoms in the interval between two UPSIT administrations) at a median inter-test
interval of 14 months. These, together with initial UPSIT scores, are plotted against age at test
in Fig 3C by using lines to connect the successive replicate scores obtained from the nine
PPND family members. In no case was olfactory dysfunction reversible. Though UPSIT scores
in these p.N279K carriers diminish as they approach their fourth decade, the UPSIT scores of
individuals with replicate assessments do not show a consistent downward trend over the sampled time intervals. Indeed, the mean of the largest difference between two successive UPSITs
in the nine subjects was 3.2 ± 1.5, and UPSIT scores were also stable in two of nine individuals
where four UPSITs were obtained over a period of 53 months. The stability of UPSIT scores,
even in subjects followed close to the age when carriers as a group show declining UPSIT
scores, suggests that it may be challenging to use serial UPSIT testing in a single individual to
precisely define the progression of olfactory dysfunction.
Olfactory dysfunction affects all odors: odor identification is irreproducible. We also
used the replicate UPSIT data in PPND kindred members to address two additional issues:
whether individual carriers lose their ability to identify specific odors, and whether their
inability to identify an odor is reproducible in successive UPSITs. We used Cohen’s kappa (κ)
as a measure of how well an individual subject could identify the same odor in replicate
UPSITs. Here, κ is used to provide a measure of intra-rater agreement that takes into account
agreement occurring by chance. Values of κ go up to one with values closer to one indicating
better agreement. Smaller values are more subject to bias. While specific benchmarks for categorizing values are arbitrary [48–50], a previously described categorization of levels of agreement based on κ values offers a useful perspective [51]: values that are negative or equal to zero
indicate poor agreement, 0.01 to 0.20 slight, 0.21 to 0.40 fair, 0.41 to 0.60 moderate, 0.61 to
0.80 substantial, and 0.81 to 1 almost perfect. Fig 4A presents box plots showing the distribution of κ values seen in 14 pairs of successive UPSITs. Moderate or better agreement existed
only when UPSIT scores were relatively high or quite low: specifically, in a control and a NMC
(UPSIT scores 33–37), and in two MCs (UPSIT scores 7 to 12). The latter two subjects consistently identified only gingerbread, however, and only poor or slight agreement existed in all
other carriers. In particular, the replicate UPSITs of PPND VI-22, the affected carrier having
outlier UPSIT scores of 33 and 30 on successive UPSITs, showed poor agreement (κ = 0.037).
We infer that, even though UPSIT scores are relatively stable, the set of odors that are unable
to be identified in an individual p.N279K carrier is neither specific nor reproducible over time.
To obtain additional support for the view that odor misidentification in carriers is not specific to one or a set of odors, and that odor identification is irreproducible, we used PCA to
evaluate whether there was any bias in the set of odors able to be identified using the UPSIT,
and also, whether subsets of study subjects showed a bias in the pattern of odors they identified
using the UPSIT. PCA using individual odor scores, each centered and scaled to have unit variance, but not using gender, age, smoking, mutation and disease status, identified distinct patterns in olfactory dysfunction. Although 12 principal components (PCs) are needed to account
for 76% of the total variance, PC1 (32.7% of variance) and PC2 (6.3% of variance) can separate
study subjects (Fig 3D).
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Fig 4. The inability to reliably and consistently identify odors is a general characteristic of olfactory dysfunction. Nine members of the PPND
kindred were administered two or more UPSITs at a median inter-test interval of 14 months. 78 EPIPARK subjects without neurodegenerative disease
(controls) and 14 EPIPARK subjects with sporadic Parkinson’s disease were administered two BSITs approximately one year apart. Boxplots indicating the
median and interquartile distribution of κ, which provides a measure of inter-rater agreement and takes into account agreement occurring by chance, is
shown for these groups (A and B). The width of the boxplots is proportional to the number of individuals in each group, noted below each boxplot. The
scores of four EPIPARK subjects are not plotted (see text). Study subjects show a range of κ values, but in all groups, the majority of individuals have κ <
0.40, indicating poor to fair agreement. That is, the set of odors that are incorrectly identified on one test shows only poor to fair agreement with the set
incorrectly identified on a second test one year later, even in instances when UPSIT or BSIT scores are similar on both tests. In the EPIPARK cohorts,
cognitive status, by itself, and age, by itself, do not explain a subject’s inability to reliably and consistently identify specific odors, as when the distribution of κ
in all study subjects is grouped by performance on the MoCA (C) or age (D), a range of κ values is seen in all groups.
doi:10.1371/journal.pone.0165112.g004

With the exception of the previously discussed outliers, PC1 distributes MCs away from
controls, while NMCs are mixed across the range of controls and MCs (Fig 3D). To evaluate
whether the separation of carriers with olfactory dysfunction by PC1 is the result of their being
unable to reliably identify specific odors in the UPSIT, the PC1 loadings (regression weights)
were examined. All are modest (mean 0.152, range 0.047–0.225), and they are distributed uniformly, with half over and half under 0.158, the value expected if each of the 40 different
UPSIT odors has an equal contribution. This is the pattern that would be expected if individuals with olfactory dysfunction are unable to reliably identify all, not just a subset of, individual
odors. Together with the results of analyzing serial UPSITs using κ, this supports the view that
olfactory dysfunction affects all UPSIT-odor classes and its onset is accompanied by increased
variability in the set of odors an individual identifies.
Kindred-specific odor identification bias. PC2 tends to distribute NMCs and controls,
but not MCs, by kindred (Fig 3D). UPSIT odors contributing to PC2 seem related to a subset
of nodes within the human odorome network [52]. The odors with appreciable positive loadings [pizza (loading = 0.24), paint thinner (0.18), cheddar cheese (0.17) and natural gas (0.16)]
seem related to the nodes odorless-cheese-sour and medicine-phenol-harsh. In the odorome
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network, these nodes connect to fruity-sweet-fat-wax, which connects to powerful-lilac. These
two nodes seem related to odors with appreciable negative loadings [grape (-0.18), grass
(-0.19), clove (-0.20), licorice (-0.25), fruit punch (-0.29), lime (-0.30), mint (-0.40), and lilac
(-0.42)]. That PC2 tends to distribute NMCs and controls by kindred suggests that an additional factor or factors can bias the pattern of odors identified in individuals without severe
olfactory dysfunction. The possible nature of such factors, e.g., genetic background, is considered in the Discussion.

Odor Identification Irreproducibility Is a General Feature of Olfactory
Dysfunction
To evaluate whether the inability to identify odors reliably and consistently using a forcedchoice test such as the UPSIT is specific to PPND carriers or is also seen in individuals with
sporadic Parkinson’s disease, and in control subjects without neurodegenerative disease, we
used κ to evaluate agreement in two BSITs administered about one year apart to 14 individuals
with sporadic Parkinson’s disease and 78 individuals with a normal neurological clinical presentation. Fig 4B shows the distribution of κ scores for each group. Four individuals (one with
Parkinson’s disease) had either all correct or all incorrect odor identifications (BSITs of 12
(n = 2) or zero (n = 2)) in both of their assessments giving κ = −1 and so these data are not
plotted in Fig 4. All other study subjects showed a range of κ values. In the group with Parkinson’s disease as well as in controls, however, the majority of individuals had κ < 0.40, which
indicates fair to poor agreement. Thus, the set of odors that were incorrectly identified on one
test did not strongly overlap with the set incorrectly identified on a second test one year later,
even in instances when BSIT scores were similar on both tests. Neither cognitive status, as evaluated by performance on the MoCA (Fig 4C) nor age (Fig 4D) explain a subject’s inability to
reliably and consistently identify specific odors, as a range of κ values are seen in all cognitivestatus and age groups evaluated in this study. We conclude from these data that odor-identification irreproducibility in forced-choice tests of olfactory function such as the UPSIT and
BSIT is a non-disease specific, general feature of olfactory dysfunction that is accelerated in
MAPT-related neurodegenerative disease.

Discussion
To characterize the salient features of olfactory dysfunction associated with MAPT mutations
that have different clinical, molecular and neuropathological consequences [19–25], we evaluated UPSITs from MCs and NMCs in FTDP-17 kindreds carrying the p.N279K or p.P301L
MAPT mutations. While we evaluated of a relatively small number of individuals, some trends
are evident. Carriers of both alleles show significant, irreversible age-dependent olfactory dysfunction prior to symptom onset, and allele-specific differences in the severity of olfactory dysfunction are not readily apparent. Strikingly, severe olfactory dysfunction (say, UPSIT  15) is
not a fully penetrant phenotype for either allele. However, the appearance of severe olfactory
dysfunction in NMCs appears to be associated with subsequent disease onset. Furthermore,
evaluation of p.N279K carriers using serial UPSITs did not reveal a gradual decrease in olfactory function, as UPSIT scores were relatively stable. This may mean that olfactory dysfunction, when measured by the UPSIT, occurs in stepwise decrements that are not easily followed.
Nonetheless, as a population, MAPT carriers typically develop substantial olfactory dysfunction during a relatively short period–one-to-two years–before symptom manifestation.
Olfactory dysfunction affects the ability to identify all odors in the forced-choice UPSIT,
and before it becomes severe, UPSIT odors are identified inconsistently. Consequently, no
inferences should be made regarding a subject’s long-term ability to identify an individual
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odor or subset of odors from the administration of a single UPSIT. To our knowledge, this is
the first report of individuals at risk for or with dementia and/or Parkinson’s disease to show
irreproducible odor identification in a forced-choice smell test. While the analysis of serial
UPSITs in the PPND kindred revealed odor-identification irreproducibility in a forced-choice
test as a feature of olfactory dysfunction, this feature is a non-disease specific, general characteristic of olfactory dysfunction. Aging subjects with sporadic Parkinson’s disease, as well as
subjects with no evidence of neurodegenerative disease frequently are unable to identify the
same set of odors in replicate BSITs carried out about a year apart. Neither cognitive status nor
age, by themselves, explain a subject’s inability to reliably and consistently identify specific
odors.

Potential study limitations
One important limitation of this study is its sample size, and the unavailability of mutationnegative controls in the Gdańsk family, which necessitated the comparison of p.P301L mutation carriers to pair-matched controls. Also, while the PPND family is large with many affected
and at-risk individuals, replicate UPSITs could be obtained only in nine of the 31 carriers and
controls. Still, in each of two NMCs, four tests spanning 53 months had only 6.6% average variation and did not reveal a uniform decline in olfactory function (Fig 3C). This suggests that
total UPSIT scores from single tests are reliable measures of olfactory function. Nonetheless,
increasing the sample size, in particular assessing a greater number of individuals with the p.
P301L, or with additional MAPT alleles, and longitudinally assessing NMCs and controls over
longer time spans would provide more confidence that MAPT-related olfactory dysfunction
does not demonstrate allele specificity and also provide more insight into whether the UPSIT
is effective at documenting the onset of olfactory dysfunction.
A second limitation is that interpretation of UPSIT questions by a subject may be influenced by different cultural norms. However, previous studies demonstrated that UPSIT score
differences were independent of ethnicity and education level [53].
A third concern is that cognitive impairment is often present in FTDP-17, just as it is in
other FTD syndromes, and smell identification requires not only primary sensory processing,
but also retrieving information about the possible smell source from semantic memory [54].
Since abnormal UPSIT scores could reflect overall cognitive impairment, MCs with severe
cognitive impairment were excluded. Furthermore, the presence of a true deficit in odor identification is clear from the deficient performance of NMCs lacking cognitive and motor manifestations. It would be useful to assess semantic memory with respect to olfactory dysfunction
in these and other kindreds with inherited parkinsonism/dementia using a uniform neuropsychological assessment.
A fourth concern is that the tests selected to assess olfactory function might bias our results.
Other approaches to evaluate olfactory function might reveal additional or different attributes
of olfactory dysfunction. For example, odor-identification irreproducibility in successive
UPSITs and BSITs could be related specifically to the forced-choice nature of these tests, or
more generally, to the imperfect reliability of psychophysical tests of olfaction. Some variance
among test items is expected, as the test-retest reliability of the UPSIT is around 0.9 (accounting for ~80% of the variability), while that of the BSIT is around 0.75 (accounting for 56% of
the variability) [55]. While tests with more items generally are more reliable and sensitive to
olfactory deficits, the mechanism by which olfactory information is processed also may contribute to odor-identification irreproducibility, as discussed in the following section. It would
therefore be useful to evaluate this finding using other methodologies to better characterize its
underlying basis.

PLOS ONE | DOI:10.1371/journal.pone.0165112 November 17, 2016

15 / 23

Odor-Identification Irreproducibility in MAPT Disease

Potential mechanisms underlying olfactory dysfunction in mapt kindreds
The etiology of olfactory dysfunction in neurodegenerative disease remains unclear. While
environmental factors have been proposed [56], this study supports a demonstrable role for
genetic factors, as age-related olfactory dysfunction clearly is associated with MAPT mutations.
Discerning which aspects of the mechanism of olfactory perception and the processing of
olfactory information are affected in mutation carriers remains challenging due to gaps in our
understandings of normal peripheral odor coding and the mechanism for processing information from olfactory perception. Previously published studies have evaluated the consistency
and characteristics of odor identification and olfactory function in both sporadic and familial
forms of Parkinson’s disease and in other neurodegenerative and neurological diseases (see
[5,6,57–62] for review, see also [14,16,17,63–85]). Some studies suggest a diagnostic utility for
odor-identification testing, sometimes in concert with imaging-based tests, others argue for
using odor-identification tests with a limited subset of odors or raise issues related to predictive reliability. Our findings contribute to this discussion. Some of the inconsistency in odor
identification that we observe may reflect variability in how odors are initially detected. At the
peripheral level, we know that odors are detected using olfactory neurons that express single
odorant receptors [86] and that odors are identified using combinatorial coding after neurons
with the same odorant receptor transmit odor detection to a specific set of glomeruli in the
olfactory bulb [87]. Inconsistent patterns of odor identification may reflect variation in the
spectrum, distribution and density of olfactory receptors coupled with variability in the functional activation of single receptors due to the unequal intensities of odorants presented in different tests of olfactory function, including the UPSIT and BSIT. Not only are odorants often
composed of multiple chemical compounds, single odorant receptors respond to multiple
chemical compounds and multiple odorant receptors are activated by single chemical odorants
[52]. Given the “many-to-many” mapping of odorants to receptors, it would be useful to
understand whether single-compound odorants have greater consistency or reliability than
multiple-compound odorants, assuming that multiple-compound odorants target a broader
array of receptor types.
Since odorant receptor neurons are replaced over periods of weeks to months, and newly
born neurons must select among temporarily expressed multiple odorant receptor proteins
[88], a related explanation for the onset of inconsistency in the identification of individual
odors is that it reflects dynamic processes at the peripheral sensory level. For example, there
could be changes in the availability of certain types of odorant receptor neurons, or in the
strength of their inputs to glomeruli. This could alter the balance of inputs from the set of different olfactory receptors required to correctly identify an individual odor. At different times,
the specific nature of the imbalance could vary, so that an odor misidentified at one time point
would be different from an odor misidentified at a later time point. Since odor-identification
irreproducibility is also seen in individuals without evidence of neurodegenerative disease, it is
noteworthy that this hypothesis does not require a neurodegenerative process, only an alteration to the normal dynamics of the population of olfactory receptor neurons and the strengths
of their projections. If such a process occurs in MAPT carriers, perhaps it is accelerated or
accentuated at an earlier age due to the neurodegenerative process, or contributes to already
ineffective or inaccurate downstream processing of the signals provided by odor detection.
The identification of an odor also requires cognitive processing that occurs at multiple levels in the brain, with rich cortical involvement as well as the involvement of subcortical structures with reciprocal connections [89,90]. Timing of neuronal activity in the olfactory bulb can
also convey odor information [91]. While visual, auditory, and somatosensory systems employ
topographic neural maps as a fundamental mechanism to convert stimulus parameters to
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neuronal spatial relationships, odor information is not organized topographically in the olfactory system. It has been proposed to be dependent on distributive rather than hierarchical
afferent connectivity and modulation from multiple neuromodulatory centers for olfactory
processing [92], and as a result, is more “error-prone” than other sensory systems. Substantial
to severe olfactory dysfunction in MAPT carriers could therefore reflect deficits at one or more
of these levels and result in an increase in errors in odor identification. Imaging methods such
as diffusion tensor imaging and fractional anisotropy, which assess connectivity patterns
[93,94], may help assess the neuronal substrates of olfactory dysfunction [95–99] and delineate
mutation-specific effects.
The UPSIT and the BSIT, as forced-choice tests, require a subject to select between four single-word descriptions of an odor. Yet perceived odors, even those associated with single odorant molecules, are often described using multiple terms related to contextual memories,
reflecting their perception as an “ensemble of components” [52]. They can be associated with
specific experiences or objects through retrieving information from semantic memory. Therefore, the onset of inconsistency in a carrier’s identification of individual odors could also
reflect a growing deficit in higher-order processing of sensory information, that is, interpreting
the set of presumably balanced inputs from a set of olfactory receptors. Since odor-identification irreproducibility is also seen in a cohort of subjects free of neurodegenerative disease, it
may also reflect variation in the inherently error-prone perception mechanism.

Potential mechanisms underlying biased odor-identification
Especially since odor identification is irreproducible, it is intriguing that PC2 was able to use a
subset of odors to separate NMCs and controls by family (Fig 3D). That PC2 does not clearly
separate MCs by family likely reflects their uniformly poor performance on the UPSIT, but
multiple explanations are possible for why NMCs and controls can be separated by family.
This could reflect cultural bias, chance effects from the small sample size, environmental differences, or, since we know that there is variation in the set of functional odorant receptors
present in the genome, differences in genetic background unrelated to a MAPT allele. Some
support for the contributions of genetic background comes from seeing that the controls for
the PPND kindred, who were mutation-negative family members, cluster with PPND NMCs.
Also, the apparent relationship between UPSIT odors having significant contributions to PC2
and nodes in the human odorome [52] supports the hypothesis that this separation may reflect
differences in either the subjects’ odorant receptor repertoire and/or differential connectivity
patterns among brain regions involved in olfaction. The influence of shared genetic background on phenotypes in kindreds with mutations causing neurodegenerative disease has
been highlighted previously. For example, a large family with a PINK1 mutation shares a pattern of hyperechogenicity in the substantial nigra [100]. Clustering within a family also is
entirely consistent with the recent finding that “olfactory fingerprints”––measures developed
from matrices of perceived odorant similarity derived from descriptors applied to individual
odorants––can reveal meaningful non-olfactory genetic information as they are related to
HLA matching [101].

Perspective for future research
The analysis of rare kindreds with highly penetrant mutations causing neurodegenerative disease is invaluable for characterizing the development and severity of disease manifestations,
many of which, like olfactory dysfunction, have been proposed as biomarkers of a prodromal
disease state. Furthermore, longitudinal assessment of rare kindreds with monogenic disease
forms can help uncover characteristics such as the odor-identification irreproducibility
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discovered here, which can be difficult to demonstrate in sporadic disease, whose nature is
much more heterogeneous. In addition, using such kindreds to investigate olfactory function
along with other biomarkers of disease progression, such as functional imaging, should provide a path towards a more comprehensive understanding of olfaction, as well as how olfactory
dysfunction occurs neurodegenerative disease.
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